Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Motzer, R. J.
Right arrow Articles by Bukowski, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Motzer, R. J.
Right arrow Articles by Bukowski, R.

Clinical Cancer Research, Vol 4, Issue 5 1183-1191, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma

RJ Motzer, A Rakhit, LH Schwartz, T Olencki, TM Malone, K Sandstrom, R Nadeau, H Parmar and R Bukowski
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

Patients with advanced renal cell carcinoma were treated in a Phase I trial with escalating doses of recombinant human interleukin-12 (rHuIL-12) given on days 1, 8, and 15 of each 28-day cycle. Treatment in the initial dose scheme consisted of a fixed dose with dose levels of 0.1, 0.5, and 1.0 microg/kg given to cohorts composed of three or six patients. On the basis of the toxicity profile, a second scheme (up-titration) was undertaken wherein rHuIL-12 was escalated for each patient from week 1 to week 2, to a target dose given week 3 and thereafter; cohort target dose levels were 0.5, 0.75, 1.0, 1.25, and 1.5 microg/kg. Fifty-one patients were treated: 32 (63%) had prior cytokine therapy and 19 (37%) had received no prior systemic therapy. The maximum tolerated dose for the fixed dose scheme was 1.0 microg/kg. Dose-limiting toxicities included increase in transaminase concentration, pulmonary toxicity, and leukopenia. The most severe toxicities occurred with the first injection and were milder upon further treatment. With the up-titration dose scheme, the maximum tolerated dose was reached at 1.5 microg/kg, and dose-limiting toxicity consisted of an increase in serum transaminase levels. At the maximum tolerated dose of 1.5 microg/kg, serum IL-12 levels increased to a mean peak level of 706 pg/ml. Serum levels of IFN-gamma increased to a mean peak level of about 200 pg/ml at 24 h after the first maintenance dose of 1.5 microg/kg. The best responses were as follows: one patient had complete response, 34 patients were stable, 14 patients showed progression, and 1 patient was inevaluable. In conclusion, rHuIL-12 was relatively well tolerated when administered by s.c. injection. The recommended dose according to the up-titration schedule of rHuIL-12 (microg/kg) for Phase II trials was as follows: cycle 1, 0.1 (day 1), 0.5 (day 8), 1.25 (day 15); cycle 2 onwards, 1.25. Phase II trials of rHuIL-12 were initiated in previously untreated patients with renal cell carcinoma and in patients with melanoma.


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
M. Del Vecchio, E. Bajetta, S. Canova, M. T. Lotze, A. Wesa, G. Parmiani, and A. Anichini
Interleukin-12: Biological Properties and Clinical Application
Clin. Cancer Res., August 15, 2007; 13(16): 4677 - 4685.
[Abstract] [Full Text] [PDF]

Home page
 CVIHome page
N. G. Cortes-Perez, S. Ah-Leung, L. G. Bermudez-Humaran, G. Corthier, J.-M. Wal, P. Langella, and K. Adel-Patient
Intranasal Coadministration of Live Lactococci Producing Interleukin-12 and a Major Cow's Milk Allergen Inhibits Allergic Reaction in Mice
Clin. Vaccine Immunol., March 1, 2007; 14(3): 226 - 233.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Ansell, S. M. Geyer, M. J. Maurer, P. J. Kurtin, I. N.M. Micallef, P. Stella, P. Etzell, A. J. Novak, C. Erlichman, and T. E. Witzig
Randomized Phase II Study of Interleukin-12 in Combination with Rituximab in Previously Treated Non-Hodgkin's Lymphoma Patients.
Clin. Cancer Res., October 15, 2006; 12(20): 6056 - 6063.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Oniki, H. Nagai, T. Horikawa, J. Furukawa, M. L. Belladonna, T. Yoshimoto, I. Hara, and C. Nishigori
Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.
Cancer Res., June 15, 2006; 66(12): 6395 - 6404.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
R. F. Little, J. M. Pluda, K. M. Wyvill, I. R. Rodriguez-Chavez, G. Tosato, A. T. Catanzaro, S. M. Steinberg, and R. Yarchoan
Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma
Blood, June 15, 2006; 107(12): 4650 - 4657.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
T. Khan, J. K. Stauffer, R. Williams, J. A. Hixon, R. Salcedo, E. Lincoln, T. C. Back, D. Powell, S. Lockett, A. C. Arnold, et al.
Proteasome Inhibition to Maximize the Apoptotic Potential of Cytokine Therapy for Murine Neuroblastoma Tumors
J. Immunol., May 15, 2006; 176(10): 6302 - 6312.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. Khan, J. A. Hixon, J. K. Stauffer, E. Lincoln, T. C. Back, J. Brenner, S. Lockett, K. Nagashima, D. Powell, and J. M. Wigginton
Therapeutic Modulation of Akt Activity and Antitumor Efficacy of Interleukin-12 Against Orthotopic Murine Neuroblastoma
J Natl Cancer Inst, February 1, 2006; 98(3): 190 - 202.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. N. Torrero, W. G. Henk, and S. Li
Regression of High-Grade Malignancy in Mice by Bleomycin and Interleukin-12 Electrochemogenetherapy
Clin. Cancer Res., January 1, 2006; 12(1): 257 - 263.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M.L. van Herpen, J. A.W.M. van der Laak, I. J. M. de Vries, J. H. van Krieken, P. C. de Wilde, M. G.J. Balvers, G. J. Adema, and P. H.M. De Mulder
Intratumoral Recombinant Human Interleukin-12 Administration in Head and Neck Squamous Cell Carcinoma Patients Modifies Locoregional Lymph Node Architecture and Induces Natural Killer Cell Infiltration in the Primary Tumor
Clin. Cancer Res., March 1, 2005; 11(5): 1899 - 1909.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Mekhail, R. M. Abou-Jawde, G. BouMerhi, S. Malhi, L. Wood, P. Elson, and R. Bukowski
Validation and Extension of the Memorial Sloan-Kettering Prognostic Factors Model for Survival in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
J. Clin. Oncol., February 1, 2005; 23(4): 832 - 841.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
R. Salcedo, J. K. Stauffer, E. Lincoln, T. C. Back, J. A. Hixon, C. Hahn, K. Shafer-Weaver, A. Malyguine, R. Kastelein, and J. M. Wigginton
IL-27 Mediates Complete Regression of Orthotopic Primary and Metastatic Murine Neuroblastoma Tumors: Role for CD8+ T Cells
J. Immunol., December 15, 2004; 173(12): 7170 - 7182.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Younes, B. Pro, M. J. Robertson, I. W. Flinn, J. E. Romaguera, F. Hagemeister, N. H. Dang, P. Fiumara, E. M. Loyer, F. F. Cabanillas, et al.
Phase II Clinical Trial of Interleukin-12 in Patients with Relapsed and Refractory Non-Hodgkin's Lymphoma and Hodgkin's Disease
Clin. Cancer Res., August 15, 2004; 10(16): 5432 - 5438.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Alatrash, T. E. Hutson, L. Molto, A. Richmond, C. Nemec, T. Mekhail, P. Elson, C. Tannenbaum, T. Olencki, J. Finke, et al.
Clinical and Immunologic Effects of Subcutaneously Administered Interleukin-12 and Interferon Alfa-2b: Phase I Trial of Patients With Metastatic Renal Cell Carcinoma or Malignant Melanoma
J. Clin. Oncol., July 15, 2004; 22(14): 2891 - 2900.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. van Herpen, M. Looman, M. Zonneveld, N. Scharenborg, P. C. de Wilde, L. van de Locht, M. A. W. Merkx, G. J. Adema, and P. H. De Mulder
Intratumoral Administration of Recombinant Human Interleukin 12 in Head and Neck Squamous Cell Carcinoma Patients Elicits a T-Helper 1 Profile in the Locoregional Lymph Nodes
Clin. Cancer Res., April 15, 2004; 10(8): 2626 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Pelloso, K. Cyran, L. Timmons, B. T. Williams, and M. J. Robertson
Immunological Consequences of Interleukin 12 Administration after Autologous Stem Cell Transplantation
Clin. Cancer Res., March 15, 2004; 10(6): 1935 - 1942.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, J. Bacik, L. H. Schwartz, V. Reuter, P. Russo, S. Marion, and M. Mazumdar
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., February 1, 2004; 22(3): 454 - 463.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Satoh, T. Saika, S. Ebara, N. Kusaka, T. L. Timme, G. Yang, J. Wang, V. Mouraviev, G. Cao, E. M. A. Fattah, et al.
Macrophages Transduced with an Adenoviral Vector Expressing Interleukin 12 Suppress Tumor Growth and Metastasis in a Preclinical Metastatic Prostate Cancer Model
Cancer Res., November 15, 2003; 63(22): 7853 - 7860.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. M. van Herpen, R. Huijbens, M. Looman, J. de Vries, H. Marres, J. van de Ven, R. Hermsen, G. J. Adema, and P. H. De Mulder
Pharmacokinetics and Immunological Aspects of a Phase Ib Study with Intratumoral Administration of Recombinant Human Interleukin-12 in Patients with Head and Neck Squamous Cell Carcinoma: A Decrease of T-bet in Peripheral Blood Mononuclear Cells
Clin. Cancer Res., August 1, 2003; 9(8): 2950 - 2956.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. I. Albu, A. Jones-Trower, A. M. Woron, K. Stellrecht, C. C. Broder, and D. W. Metzger
Intranasal Vaccination Using Interleukin-12 and Cholera Toxin Subunit B as Adjuvants To Enhance Mucosal and Systemic Immunity to Human Immunodeficiency Virus Type 1 Glycoproteins
J. Virol., May 15, 2003; 77(10): 5589 - 5597.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. E. A. Portielje, C. H. J. Lamers, W. H. J. Kruit, A. Sparreboom, R. L. H. Bolhuis, G. Stoter, C. Huber, and J. W. Gratama
Repeated Administrations of Interleukin (IL)-12 Are Associated with Persistently Elevated Plasma Levels of IL-10 and Declining IFN-{gamma}, Tumor Necrosis Factor-{alpha}, IL-6, and IL-8 Responses
Clin. Cancer Res., January 1, 2003; 9(1): 76 - 83.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. J. Robertson, D. Pelloso, R. Abonour, R. A. Hromas, R. P. Nelson Jr., L. Wood, and K. Cornetta
Interleukin 12 Immunotherapy after Autologous Stem Cell Transplantation for Hematological Malignancies
Clin. Cancer Res., November 1, 2002; 8(11): 3383 - 3393.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. M. Ansell, T. E. Witzig, P. J. Kurtin, J. A. Sloan, D. F. Jelinek, K. G. Howell, S. N. Markovic, T. M. Habermann, G. G. Klee, P. J. Atherton, et al.
Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma
Blood, January 1, 2002; 99(1): 67 - 74.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
K. S. Wang, E. Zorn, and J. Ritz
Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation
Blood, June 15, 2001; 97(12): 3860 - 3866.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer, A. Rakhit, M. Ginsberg, K. Rittweger, J. Vuky, R. Yu, S. Fettner, and L. Hooftman
Phase I Trial of 40-kd Branched Pegylated Interferon Alfa-2a for Patients With Advanced Renal Cell Carcinoma
J. Clin. Oncol., March 1, 2001; 19(5): 1312 - 1319.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. L. Worth, S.-F. Jia, Z. Zhou, L. Chen, and E. S. Kleinerman
Intranasal Therapy with an Adenoviral Vector Containing the Murine Interleukin-12 Gene Eradicates Osteosarcoma Lung Metastases
Clin. Cancer Res., September 1, 2000; 6(9): 3713 - 3718.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
R. Mortarini, A. Borri, G. Tragni, I. Bersani, C. Vegetti, E. Bajetta, S. Pilotti, V. Cerundolo, and A. Anichini
Peripheral Burst of Tumor-specific Cytotoxic T Lymphocytes and Infiltration of Metastatic Lesions by Memory CD8+ T Cells in Melanoma Patients Receiving Interleukin 12
Cancer Res., July 1, 2000; 60(13): 3559 - 3568.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
R. Ohno, Y. Yamaguchi, T. Toge, T. Kinouchi, T. Kotake, M. Shibata, Y. Kiyohara, S. Ikeda, I. Fukui, A. Gohchi, et al.
A Dose-Escalation and Pharmacokinetic Study of Subcutaneously Administered Recombinant Human Interleukin 12 and Its Biological Effects in Japanese Patients with Advanced Malignancies
Clin. Cancer Res., July 1, 2000; 6(7): 2661 - 2669.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
J. A. Gollob, J. W. Mier, K. Veenstra, D. F. McDermott, D. Clancy, M. Clancy, and M. B. Atkins
Phase I Trial of Twice-Weekly Intravenous Interleukin 12 in Patients with Metastatic Renal Cell Cancer or Malignant Melanoma: Ability to Maintain IFN-{{gamma}} Induction Is Associated with Clinical Response
Clin. Cancer Res., May 1, 2000; 6(5): 1678 - 1692.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
J. E. A. Portielje, W. H. J. Kruit, M. Schuler, J. Beck, C. H. J. Lamers, G. Stoter, C. Huber, M. d. Boer-Dennert, A. Rakhit, R. L. H. Bolhuis, et al.
Phase I Study of Subcutaneously Administered Recombinant Human Interleukin 12 in Patients with Advanced Renal Cell Cancer
Clin. Cancer Res., December 1, 1999; 5(12): 3983 - 3989.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
L. S. Peng, M. L. Penichet, and S. L. Morrison
A Single-Chain IL-12 IgG3 Antibody Fusion Protein Retains Antibody Specificity and IL-12 Bioactivity and Demonstrates Antitumor Activity
J. Immunol., July 1, 1999; 163(1): 250 - 258.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1998 by the American Association for Cancer Research.